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tendencies to accumulate in tumor tissues 
to a greater extent than they do in normal 
tissues. On the other hand, irradiation 
light (in the red or near IR region) used 
for exciting the PS can be tightly focused 
on the tumor regions, essentially assuring 
the selective generation of singlet oxygen. 
Moreover, some other advantages of PDT, 
such as enhancement in the immune 
response[2] and minimally invasive treat-
ment methods,[3] make PDT very attractive 
in clinical applications compared to con-
ventional therapies.
Earlier PSs employed in PDT were 
based on porphyrins. In fact, the first PS-
approved by the FDA in 1995 for PDT of certain types of can-
cers was hematoporphyrin, an endogenous porphyrin obtained 
by acidic hydrolysis of hemoglobin. Within the last two dec-
ades, highly diverse types of dyes have been studied as potential 
PSs for PDT. Fluorescence emission and intersystem crossing 
to the triplet manifold of a PS are two major photophysical pro-
cesses that take place after forming the singlet excited states 
of PSs. Owing to this factor, fluorescence emission competes 
with ISC and following singlet oxygen generation processes. 
However, these outcomes are not mutually exclusive (Figure 1). 
Thus, it is possible for a PS to participate in high yield of ISC 
and singlet oxygen production while at the same time having a 
remarakable fluorescence quantum yield. As a result, PSs can 
serve as theranostic agents by displaying the dual functions of 
fluorescence imaging and photodynamic activity (vide infra).
The focus of this feature article is on new PSs, termed acti-
vatable photosensitizers (aPSs), which remain in a passive 
state even under light irradiation. However, aPSs are acti-
vated at the site where therapy is desired by tumor-associated 
stimuli.[4,5] Since aPSs can have their PDT and tumor imaging 
capabilities at the same time, they rejuvenate the field of PDT 
by making it highly possible to reduce the side effects and 
unselective killing of healthy cells. Below, we present a current 
summary of the progress that has been made in the devel-
opment of aPSs as phototheranostic agents to assess tumor 
microenvironments.
2. Design of aPSs
2.1. A Palette of Dyes
Porphyrin-based substances, whose structures contain four 
pyrrole rings conjugated by methine bridges in a cyclic con-
figuration (Figure 2), are the most common PSs used in 
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Photodynamic action, a term that was introduced at the turn of 
the 20th century, is at the core of photodynamic therapy (PDT).[1] 
Upon light irradiation, certain dyes (i.e., photosensitizers, PS) 
undergo intersystem crossing (ISC) and rapidly form their tri-
plet excited states. The triplet-excited state energy is then trans-
ferred to ground state (triplet) molecular oxygen (Figure 1) to 
generate singlet-excited state of oxygen (singlet oxygen). The 
half-life of singlet oxygen in aqueous milieu is about 1 ms and 
it is cytotoxic as a result of its high reactivity towards several 
vital biomolecules Thus, PDT is a promising cancer treatment 
modality in which the therapeutic action can be satisfied by 
generating singlet oxygen in tumors regions. One important 
contribution to the critically needed tumor selectivity of PDT 
is associated with the fact that PSs, which can be designed and 
constructed with targeting groups (active targeting strategy) 
or nano-delivery systems (passive targeting strategy), have 
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PDT. Because of their 18 π-electron aromatic macrocyclic 
structures, porphyrins typically have characteristic elec-
tronic absorption spectra with characteristic Q bands in the 
500–700 nm region and a Soret band around 400 nm.[6,7] 
With appropriate modification, the basic structure can be 
transformed into porphyrin derivatives or other porphyri-
noids that have specific photoactivities. For example, chlorin 
is a reduced form of porphyrin, which is obtained by reduc-
tion of one the peripheral cross-conjugated bond.[8] Owing 
to the change in symmetry that is brought by reduction, the 
Q-bands in chlorins are red shifted and have large extinction 
coefficients.[8]
Phthalocyanines (Pcs), on the other hand, are related to 
tetraazaporphyrins in that they possess four Schiff base rather 
than methane bridges connecting the pyrrole rings (Figure 2). 
Since their discovery in 1907 by Brown and Tcheriac,[9] Pcs have 
been subjected to numerous studies focusing on ways to opti-
mize their photophysical and photochemical properties.[10,11] 
Pcs are well suited as PSs for bioimaging and PDT because of 
their tunable photophysical properties and more efficient gen-
eration of singlet oxygen compared to those of porphyrins.[12,13] 
Because they have an extended conjugated electronic struc-
ture, Pcs exhibit enhanced absorption at wavelengths around 
670 nm (ε ≈ 105 L mol−1 cm−1), which are longer than those 
of most porphyrins (λmax ≈ 610 nm, ε ≈ 5 × 103 L mol−1 cm−1) 
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and that penetrate deeper into biological tissues.[14] Specificity 
required for the applications of Pcs can be governed by modi-
fication of the peripheral aromatic rings, by the nature of cen-
tral chelated metal ions and even by altering the axial ligands. 
Pcs that have been probed as PSs for PDT include derivatives 
of zinc(II)-phthalocyanine (ZnPc), silicon(IV)-phthalocyanine 
(SiPc), and aluminum(III)-phthalocyanine (AlPc).[15] In recent 
years, many ZnPc- and SiPc-based PSs have been developed 
for potential applications in near-infrared fluorescence imaging 
and PDT.
BODIPY dyes are relatively recent addi-
tions to the PS arsenal (Figure 2). These sub-
stances have remarkable fluorescence prop-
erties, which make them highly attractive 
for bioimaging applications.[16–18] It is also 
possible to alter the excited state dynamics of 
BODIPYs by suitable structural modifications 
in such a way that effective ISC and conse-
quential singlet oxygen generation become 
more efficient. One method of enhancing ISC 
involves introduction of heavy atoms (eg., bro-
mine and iodine) onto the BODIPY core.[19,20] 
Efficient singlet oxygen generation along with 
other prominent characteristics, such as tun-
able excitation wavelengths, high extinction 
coefficients, rapid cellular uptake, significant 
Adv. Funct. Mater. 2017, 27, 1604053
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Figure 1. Relevant photophysical events involved in photosensitized 
formation of singlet molecular oxygen, including photodynamic action. 
Red arrows denote photonic and black arrows (solid or dashed) denote 
non-radiative (nr) processes. A: absorption, F: fluorescence, P: phospho-
rescence, ET: energy transfer, PET: photoinduced electron transfer, CR: 
charge recombination, ISC: intersystem crossing.
Figure 2. Parent structures of the most commonly used dyes in activatable PS design. Left: 
porphin, middle: phthalocyanine (Pc), right: BODIPY. BODIPY in the above form, absorbs near 
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photostability and ease of functionalization, make BODIPY 
derivatives popular PSs in PDT applications.[19,20] Recently, a 
new generation of BODIPY-based PSs has been developed that 
undergo efficient ISC and PDT action without requiring the 
presence of heavy atom substituents on the core structure.[21]
2.2. Low pH of Tumor Microenvironments Activates  
Cancer­Specific Imaging and PDT
Tumor tissues have unique microenvironments that are slightly 
acidic, as reflected in the fact that the extracellular pH in these 
tissues is usually lower (pH 6.5 to 7.2) than that in normal tis-
sues (pH 7.4).[22] This phenomenon is a consequence of the 
greater activity of glycolysis and plasma membrane proton-
pumps in cancer cells, which elevate the generation of lactic 
acid.[23] Therefore, the utilization of PSs that are highly fluo-
rescent and promote singlet oxygen production at acidic pHs, 
but are less active at pH ca. 7.4, would facilitate cancer-specific 
imaging and PDT.
By using this reasoning, Ju et al. designed novel tar-
geted PSs, which contain a pH-activatable theranostic nano- 
platform (cRGD-NEt2Br2BDP NP), by encapsulating diethyl-
amino-phenyl and -bromophenyl substituted aza-BODIPYs 
(Figure 3a) into a cyclic RDG (cRDG) peptide-poly(ethylene 
glycol)-block-poly(lactic acid) micelle.[24] The cRDG nano micelle 
shells of these PSs ensures that they target αvβ3 integrin-rich 
cancer cells. In accord with the design features, these PSs 
undergo both singlet oxygen generation (ΦΔ = 56%) and NIR 
fluorescence emission at 925 nm selectively under slightly 
acidic conditions (pH < 7.0). At these pHs, protonation of 
dimethylaminoaryl groups takes place to block photo-induced 
electron transfer (PET) from the amine donor to the excited 
BODIPY chromophore. Importantly, implementation of one of 
these PSs, aza-BODIPY-based NEt2Br2BDP (Figure 3), enables 
selective detection of NIR fluorescence emission only around 
tumor regions in a U87MG tumor-bearing mouse.
The important features of this imaging system are that it 
displays a high tumor-to-background ratio (10-fold, 8 h after 
intravenous injection) and retention time (16 h). The use 
of NEt2Br2BDP in in vivo PDT was also explored using the 
same mouse model. Upon 808 nm laser irradiation, a dra-
matic decrease in tumor size was detected as a result of singlet 
oxygen-mediated necrosis of cancer cells in a lysosome-asso-
ciated pathway. Additionally, NEt2Br2BDP enables tracking of 
the efficacy of PDT in a self-reporting manner by monitoring 
the decrease in fluorescence intensity in the tumor region after 
the therapeutic action takes place (Figure 3b, c).
Another pH-responsive BODIPY-based PDT system was 
developed by Wang and co-workers. In this construct, water-
soluble pillar[5]arene was used as a host (carrier) for a diiodo-
BODIPY derivative that contains a quaternary ammonium 
tail.[25] Supramolecular vesicles (pseudorotaxane) formed with 
pillar[5]arene and the modified dye are highly stable under 
physiological conditions but undergo disassembly in an acidic 
environment to release the dye. In a proof of principle study, 
the vesicles were found to be cytotoxic only to A549 cancer cells 
under 690 nm irradiation, suggesting that they disassemble 
Adv. Funct. Mater. 2017, 27, 1604053
www.afm­journal.de www.advancedsciencenews.com
Figure 3. a) Structure of the pH-activatable aza-BODIPY-based PS. b) T/N tissue fluorescence ratios of U87MG tumor-bearing mice with respect 
to time before and after PDT treatment. c) In vivo PDT action and monitoring the therapeutic efficacy on U87MG tumor-bearing mice with cRGD-
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under the slightly acidic conditions present in the cell to lib-
erate the PDT-active diiodo-BODIPY derivative. Also, the vesi-
cles can be simultaneously loaded with the well-known cancer 
chemotherapy drug doxorubicin (DOX). The viability of the 
A549 cancer cells was found to decrease upon treatment with 
the DOX-loaded vesicles in the absence of irradiation (dark tox-
icity), indicating that efficient release of DOX from the vesicle 
takes place. Finally, cell death is more pronounced when the 
cell treated, DOX-loaded vesicles are irradiated as a result of 
chemo-photodynamic dual therapeutic action.
In 2011, Lee et al. described a very interesting molecular 
“Trojan horse” composed of a polysaccharide/chlorine e6 con-
jugate (Figure 4) that selectively switches into an active com-
plex for tumor destruction at pH 6.8.[26] This conjugate exists 
in a self-assembled, autoquenching, non-emissive, and non-PS 
active supramolecular form at high pH. Owing to the change 
occurring in its surface charge when placed into an acidic envi-
ronment, the complex is transformed to random molecules that 
are emissive and PDT active. Thus, this conjugate produced 
higher singlet oxygen at pH 6.8 or pH 6.4 than at pH 7.4. As 
a result, it showed higher phototoxicity against HeLa cells at 
acidic environment than at neutral condition. In vivo fluores-
cence imaging showed that the fluorescence signal in tumor 
tissues is fluctuating after treating with this conjugate.[26]
More recently, Liu et al. reported a pH-responsive nano-
aPS, which is composed of a complex of poly L-lysine (PLL), 
an AIEgen (tetraphenylsilole, TPS), an ACQ PS (pheophorbide 
A, PheA), and PEG with a targeting group.[27] At pH 7.4, the 
AIEgen component displays green fluorescence, while emis-
sion from the PheA moiety is quenched. In contrast, at pH 5.0, 
the PheA group emits red fluorescence and serves as a singlet 
oxygen generator, while the AIEgen-related green fluorescence 
is diminished owing to protonation and disassembly of the 
complex. These properties make this nano-aPS a potential agent 
for specific bio-imaging, cancer therapy, and self-tracking.[27]
In the same year, Battogtokh and Ko used PheA as basis for 
a nano-PS as part of a folate-targeted, albumin-PheA conjugate 
(FA-BSA-c-PheA), which contains an acid-responsive linker (cis-
aconityl).[28] Because FA has a high affinity for folate receptor 
that is overexpressed on the surface of tumor cells, the nano-
aPS has effective tumor-targeting characteristics. Moreover, the 
phototoxicity of the nano-PS is activated upon cleavage of the 
acid-responsive linker at pH 5.0. It was described that the in 
vitro phototoxicity of this nano-PS is similar to free PheA, but 
its tumor accumulation is much better than that of free PheA.[28]
The first attempt to develop ZnPc-based aPSs was made in 
2012 by Lo and co-workers,[29] who prepared a self-quenching 
ZnPc dimer linked with an mild acid responsive ketal unit. The 
photoactivity of this aPS is activated by cleavage of the ketal 
unit at pH 5.0–6.5. This process results in separating the phth-
alocyanine moieties from each other, leading to an increase flu-
orescent emission efficiency and singlet oxygen generation. In 
fact, the quenching percentages for singlet oxygen production 
and fluorescence emission for this ZnPc dimer at pH 7.4 are 
66% and 84%, respectively. Although reactivation of its photo-
physical properties at pH 5.0–6.5 occurs slowly, the ability of 
this system to generate singlet oxygen even in small amounts 
enables it to cause oxidative damage to cancer cells. Therefore, 
this ZnPc dimer is a cancer-specific pH-responsive fluorescent 
probe and PS for targeted PDT.[29]
In 2015, Huang and co-workers specially designed and pre-
pared a pH-sensitive nanohybrid (LDH-ZnPcPS4), in which a 
hydrophilic and negative ZnPcPS4 group and a cationic lay-
ered double hydroxide (LDH) are held together through elec-
trostatic interactions (Figure 5).[30] Pure ZnPcPS4 has excellent 
photophysical properties at pH 7.4 and displays a maximum 
absorption wavelength around 692 nm at pH 7.4. However, its 
fluorescence emission and singlet oxygen generation ability are 
quenched by about 80% upon loading on LDH. While LDH-
ZnPcPS4 is stable under neutral conditions, slightly acidic 
conditions induce the release of ZnPcPS4 from LDH. As a 
result, the photoactivities of ZnPcPS4 are restored to about 
60%. Observations made in in vitro studies indicate that LDH-
ZnPcPS4 possesses a greatly enhanced photocytotoxicity against 
HepG2 cells with an IC50 value of 0.053 µm as compared to that 
of pure ZnPcPS4 (1.27 µm). The strategy employed to design 
this aPS system should be applicable to the development of PSs 
that have specific tumor targeting abilities, highly activatable 
photocytotoxicities, and minimum side effects.[30]
Because of the strongly hydrophobic nature of their 
extended conjugated electronic cores, Pcs tend to aggregate 
in solution, a phenomenon that limits their applications.[31] 
Ready modification of axial ligands reduces the aggregation 
propensity of Pcs to some extent, so that SiPcs have better 
properties than do ZnPc. This reasoning led Ng et al. to 
develop several SiPc-based aPSs.[32–34] The first one explored 
was a tetraamino-SiPc, which has greatly enhanced photo-
activity efficiencies under highly acidic conditions. This fea-
ture makes tetraamino-SiPc a promising pH-sensitive fluores-
cent probe and PS for PDT.[32]
Adv. Funct. Mater. 2017, 27, 1604053
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Figure 4. Schematic illustration of a polysaccharide/drug complex. This complex assembles and undergoes autoquenching efficiently at high pH, while 
in the acidic environment of tumor tissues protonation occurs and photoactivities restored, thereby destroying the tumor. Reproduced with permis-
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2.3. Higher Intracellular GSH Concentrations in Cancer Cells 
Activates Specific Imaging and PDT
Since the aforementioned aPSs are based on the activation of 
extracellular low pH in tumor tissue, they may be destructive 
to the tumor by first destroying the non-tumor cells or biomole-
cules in the extracellular matrix of tumor tissue. Intracellular 
stimuli-activated mechanism may be a more direct strategy 
to destroy the cancer cells. As we know, the concentration of 
intracellular glutathione (GSH) is about 10 mm, which is much 
higher than it is in extracellular environments (ca. 2 µm). This 
feature can be utilized advantageously in strategies to activate 
specific intracellular drug release.[35] Moreover, GSH levels in 
tumor tissues are usually even higher than those in normal tis-
sues.[36] Thus, approaches for tumor-targeted PS release and 
activation can also be based on reactions of GSH. Recently, a 
number of drug delivery systems and fluorescence probes that 
rely on biothiol-responsive protocols have been described.[37–41] 
To the best of our knowledge, only two recent examples of this 
approach utilizing different PSs have been described.
Wu and co-workers designed caged PS and fluorescent 
reporter modules, which are covalently linked through a GSH 
responsive disulfide linker.[44] The theranostic design of these 
types of substances takes advantage of the presence of two 
chromophores operating separately as an activatable PS and a 
fluorescent reporter. Consequently, singlet oxygen generation 
and fluorescence are not operating competitively in this system, 
which enables maximization of both outputs.
One of these types of dual active systems contains a 
2,6-diiodo-BODIPY sensitizer moiety, which is inactive owing 
to singlet-excited state quenching through PET. At the same 
time, a mono-styryl BODIPY group serving as a reporter 
is almost non-emissive as a result of PET quenching of an 
internal 2,4-dinitrobenzenesulfonyl (DNBS) group that would 
have been capable of serving as an energy transfer donor. GSH, 
in high concentrations in cancer cells, promotes cleavage of the 
disulfide bond liberating the DNBS group, thus turning on its 
PS property (ΦΔ = 0.72) and increasing the emission intensity 
of the reporter group (ΦF = 0.48). This approach, in which both 
PDT and fluorescence monitoring properties are activated by 
GSH, was also shown to be applicable to HeLa cells.
In another recent approach, Turan et al. incorporated 
a DNBS quenching moiety into a dibromo-BODIPY core, 
which possesses triethyleneglycol units for improved water 
solubility (PS1) (Figure 6).[45] GSH-mediated activation of 
therapeutic action was found to take place in HCT116 cancer 
cells. Specifically, upon irradiation at 660 nm, emission from 
FITC-Annexin-V labeled membranes is observed along with 
singlet oxygen induced apoptosis of the cells (IC50 ∼ 0.02 µm). 
It is worthy of note that singlet oxygen is not always quenched 
by the PET effect, which has been reported in many triplet-
triplet annihilation upconversion system.[46–48] Our very recent 
research also indicates that some special phthalocyanines 
show fluorescence quenching induced by PET, while they still 
generate excellent singlet oxygen.
Heavy-atom free PSs have attracted great interest in recent 
years because they have minimal dark toxicity that arises from 
the presence of atoms such as bromine, iodine, and several 
lanthanides. Heavy-atom-induced dark toxicity is more pro-
nounced when high concentrations of PSs are employed, a phe-
nomenon that inherently restricts the applicable dosage of PSs 
and accordingly diminishes the efficacy of PDT. Because of this 
limitation, it is highly desirable to design PSs that have high 
ISC quantum yields but do not contain heavy atoms.
Kolemen et al. devised a GSH-activatable heavy-atom free 
PS based on an orthogonal BODIPY dimer scaffold.[21] The 
orthogonal arrangement of BODIPY moieties in this PS leads 
to a unique singlet excited state having in a doubly substituted 
tetraradical (DS-TR) electronic characteristic that facilitates ISC. 
Specifically, in this system two BODIPYs with similar electronic 
properties (symmetric BODIPY cores) are oriented orthogonally 
so that mixing of their π-systems does not occur. As a result, a 
degenerate pair of HOMOs and LUMOs exist, which is the key 
criterion for formation of DS-TR singlet excited state.[49]
Based on these results, an orthogonal dimer containing 
a reactive styrene double-bond was designed (5, Figure 7a), 
Adv. Funct. Mater. 2017, 27, 1604053
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Figure 5. Illustration of the construction of a pH-sensitive nanohybrid (LDH-ZnPcPS4) and its proposed mechanism for activation in PDT associated 
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in which one of the BODIPY core groups (BOD2) has an 
extended p-system (asymmetric dimer). This feature blocks 
formation of degenerate HOMOs and LUMOs and thus sup-
presses formation of the DS-TR state and consequent singlet 
oxygen generation.[50] GSH in cancer cells reacts with the 
styryl double bond, disrupting the extended π-conjugation 
and isolating a methylpyridinium (MP) moiety from the 
orthogonal BODIPY dimer. Upon photoexcitation of the GSH 
adduct (5-GSH), through-space charge transfer takes place 
from BOD1 to electron-deficient MP, in which BOD2 behaves 
like an orthogonal spacer (Figure 7a). It is known that when 
orbitals responsible for charge transfer transitions are well 
separated and oriented in an orthogonal arrangement, the 
transition causes a change in orbital angular momentum, 
which is compensated by a spin angular momentum change. 
This spin-state change favors ISC in the PS and promotes 
PDT action.
Singlet oxygen generation promoted by this aPS was demon-
strated by using a singlet oxygen trap method and by monitoring 
its phosphorescence at 1270 nm with the help of easily pre-
pared 5r (“always on”) that is electronically similar to the 5-GSH 
adduct, which is the pre-activated analogue of 5 (Figure 7a). The 
actual activatable PS 5 was tested using both healthy and cancer 
cells. Red emission from Annexin V-AF594 dye, seen using con-
focal microscopy, clearly indicates that intracellular activation 
of 5 occurs and that singlet oxygen induced apoptosis of HeLa 
cells is promoted (Figure 7b). The survival rates for HeLa and 
SKHep 1 cancer cells treated in this manner were found to be 
around 40%. On the other hand, non-cancerous NIH 3T3 and 
WI38 VA13 cells have an approximate 80% survival rate under 
Adv. Funct. Mater. 2017, 27, 1604053
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Figure 6. Structure of GSH-responsive PS1 bearing a DNBS group. Reproduced with permission.[45] Copyright 2014, John Wiley and Sons.
Figure 7. a) Reaction of activatable, heavy atom-free PS (5) with GSH. Structure of the pre-activated (always on) PS (5r). b) Confocal images of HeLa 
cells incubated with (5). Blue channel: DAPI, for nucleus staining, green channel: emission of the PS, red channel: Annexin V-AF594, an apoptosis 
marker. c) Survival rates of healthy cells (NIH 3T3, WI38 VA13) and of cancer cells (HeLa, SK Hep 1) which were incubated with (5) or (5r). Reproduced 











© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimwileyonlinelibrary.com1604053 (7 of 11)
identical conditions. In addition, in the case of the “always on” 
positive control, PS 5r, cell viability was 10% for both healthy 
and cancer cells (Figure 7c). HeLa cells were also treated with 
buthioninesulfoxime (BSO), a known GSH synthesis inhibitor. 
The observation of a notable cell viability increase caused by this 
inhibitor demonstrates that GSH-mediated selective activation 
of the PS in cancer cells is taking place.
Huh et al. developed a nanohybrid containing a PS (PheA), 
an Fe3O4/Au nanoparticle and a polysaccharide heparin 
(Figure 8).[42] In the hybrid, a thiolated PhA-heparin conju-
gate (H-PhA), serving as a supramolecular PS, is immobilized 
on the surfaces of Fe3O4/Au nanoparticles through gold-thiol 
bonds. The photoactivitiy of the PS is quenched by Au in the 
shell. Exchange of the thiol groups of the inactive PS on the 
Au surface with those of GSH present in cancer cells releases 
the photoactive PS. These observations suggest that this nano-
hybrid may be useful for tumor-selective PDT.[42]
Recently, Li et al. designed another GSH-responsive, targeted 
theranostic nanoparticle platform.[43] In this system, chlorin e6 
is conjugated with a matrix metalloproteinase-2 cleavable poly-
peptide and bonded to a polyethylene glycol via a GSH respon-
sive disulfide linker. Interestingly, this substance self-assembles 
to form nanoparticles. In addition, unlike free chlorin e6, the 
cytotoxicity of the nanoparticles is not lost upon irradiation. The 
results of animal experiments showed that the nanoparticles have 
significantly enhanced tumor selectivity and an increased PDT 
efficiency. As a result, this smart nanoparticle aPS system holds 
great potential for use in tumor-targeting imaging and PDT.[43]
2.4. Enzymes/Proteins Overexpressed in Cancer Cells Activate 
Specific Imaging and PDT
Over the last several years, many studies have probed the use 
of enzymes to promote the photoactivities of porphyrin-based 
aPSs. Among these systems, which consist of a disease-targeted 
linker, a PS and a quencher, the “photodynamic molecular 
beacons” (PMB) developed by Zheng and co-workers are note-
worthy.[51–61] The excited state of the PS in this aPS is efficiently 
quenched via Förster Resonance Energy Transfer (FRET) to 
a quencher that is closely positioned through a linker. When 
the linker is cleaved by a cancer-specific stimulus, such as 
an enzyme, the quencher separates from the PS associated 
with regeneration of its photoactivity. Application of the PMB 
concept to the development of tumor-targeted PSs is very 
promising because it not only enables the design of systems 
that have tumor specific PS delivery capabilities but also has 
the ability to undergo controlled activation by a cancer specific 
biomarker. In addition, this concept can also be used to design 
other activation strategies to treat diseases other than cancer.[62]
In 2011, Zheng et al. described a new class of aPSs, called 
unquenched activatable photosensitizer (QUaPS), in which sin-
glet oxygen generation is unquenched while fluorescence emis-
sion responds to a specific enzyme.[63] In this system, the PS 
porphyrin pyropheophorbide (Pyro) is conjugated to 5-carboxy-
X-rhodamine (Rox) via a linker comprised of a caspase-3 tar-
geted peptide GDEVDGSGK (Figure 9). Rox serves as a donor 
in a FRET pair with the acceptor of Pyro. Interestingly, singlet 
oxygen production by this system is not quenched prior to cas-
pase treatment but emission from the porphyrin is quenched 
by FRET. Consequently, upon Pyro excitation this QUaPS has 
enhanced photocytotoxicity against HT-29 cancer cells. The 
system can be used for ratiometric fluorescent imaging (with 
Rox excitation) of caspase-3 activation in cancer cells, fol-
lowing induction of cell death by Pyro excitation. Although 
having one recognized limitation of QUaPS, associated with 
detection interference caused by singlet oxygen induced Pyro 
self-bleaching, the method still holds great promise as novel 
feedback-oriented PDT strategy involving treating the targeted 
areas with an appropriate PS and light dose.[63]
Dong and co-workers recently described a protein-activated 
theranostic agent.[64] This system is composed of nanoparticles 
Adv. Funct. Mater. 2017, 27, 1604053
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Figure 8. Schematic illustration of GSH-responsive photoactivities of Fe3O4/Au/H-PhA nanohybrid for cancer-selective PDT. Reproduced with permis-
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(DBHA-NPs) formed by conjugation of a heavy-atom deco-
rated BODIPY with hyaluronic acid (HA) (Figure 10a), and 
it targets the HA receptor CD44, which is overexpressed in 
many cancer cells. The self-assembled, auto-quenching and 
spherical DBHA-NPs are disaggregated in HCT-116 cancer 
cells owing to overexpression of CD44. As a result, the nano-
particles display enhanced emission and they promote singlet 
oxygen generation. The behavior of this system was validated 
by its suppression of tumor growth in HCT-116 cancer cell 
bearing mouse models (Figure 10b). In A2780 cancer cells (low 
CD44 expression) the fluorescence intensity of the DBHA-NPs 
decrease gradually compared to that in HCT-116 cells proving 
that specific targeting takes place. It is concluded that uptake 
of these nanoparticles occurs selectively through CD44 receptor 
mediated endocytosis. In a report published last year, Choi et al. 
described a porphyrin-based aPS activated by cathepsin B.[65] 
In this system, chlorin e4 (Ce4) is conjugated with a closely 
posited folic acid (FA) group, which serves as a quencher, 
through a short peptide linker, which is cleaved by cathepsin 
B. This smart dual-selective theranostic agent becomes highly 
fluorescent and promotes photocytotoxicity only when the 
peptide linker is cleaved by cancer-associated cathepsin B in 
folate receptor-positive cancer cells. The results of both cell and 
animal studies indicate that this aPS is useful for dual-selective 
NIR fluorescent imaging and cancer-specific PDT.
Earlier, Nagano et al. developed an interesting enzyme-
responsive aPSs based on a small molecule dye that is capable of 
selectively inducing photooxidative damage against β-galactosidase-
expressing cancer cells.[66,67] This system, composed of a sele-
nium-substituted rhodol scaffold modified with a β-galactoside 
(HMDESeR-βGal) cancer-targeting moiety, is not photocytotoxic 
due to the influence of galactoside moiety (Figure 11). The singlet 
oxygen generation capability of HMDESeR-βGal is dramatically 
enhanced as a consequence of a structural change promoted by 
action of a cancer cell derived β-galactosidase. In a model study, 
these workers showed that when larval Drosophila melanogaster 
wing disks are treated with HMDESeR-βGal and irradiated, 
cell death takes place selectively in the posterior region where 
β-galactosidase is expressed.[66] An example of a non-enzymatic 
protein acting as an effector for aPS is seen in studies by Jin 
et al. The targeting and triggered activatable system is composed 
of a folate-porphysome assembled from porphyrin-phospholipid 
conjugates.[68] The folate receptor-targeting porphysome containing 
a FA-PEG moiety in the porphysome base displays nano structure-
induced super-quenching of photoactivities of the porphyrin 
(>90%) as compared with the corresponding disassembled form of 
Adv. Funct. Mater. 2017, 27, 1604053
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Figure 9. Structure of an aPS with a caspase-3 cleavable linker.
Figure 10. a) Enzyme-activated PS (DBHA-NPs). b) Time-dependent tumor volume change in the HCT-116 mice models in the presence of light or in 
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the nanohybrid. FA facilitated cellular uptake of the nanoparticles 
into cancer cells leads to efficient disruption of the nanohybrids 
in the cells that blocks quenching of PS fluorescent emission and 
singlet oxygen production. In both cell and animal studies, FA-
porphysome were observed to have folate receptor-targeted PDT 
activity, which demonstrates the applicability of targeting-respon-
sive PDT reactivation of porphysome for cancer-specific therapy.[68]
Several non-enzymatic proteins are overexpressed in both 
tumor and non-tumor cells in cancer tissues. For example, 
the biotin receptor is overexpressed to a greater extent than 
the folate receptor in a large number of cancer cell lines.[69–71] 
Tumor-associated macrophages (TAMs) highly express scavenger 
receptor-A (SR-A).[72,73] Vascular endothelial growth factor 
receptor (VEGFR) and αvβ3-integrin also represent excellent 
targets for specific PS delivery systems.[74–77] Thus, many poten-
tial approaches exist to construct special aPSs for bioimaging 
and targeted PDT based on the non-enzymatic protein stimuli.
2.5. Other Activation Methods
Besides those based on protein, pH, and thiol responses, other 
mechanisms can be employed to stimulate aPSs. For example, in 
2014 Choi et al. described a novel theranostic agent for specific 
imaging and therapy of the atherosclerotic lesions.[78] The system 
is comprised of macrophage-targeted theranostic nanoparticles 
(MacTNPs) formed by conjugating Ce6 to hyaluronic acid. 
Fluorescence and singlet oxygen generation by MacTNPs in 
the native state is inhibited by a self-quenching effect between 
the conjugated PSs. Upon internalization of 
MacTNPs into the activated macrophages, 
excess reactive oxygen species (ROS) in the 
cells degrades the nanoparticles by cleaving 
the hyaluronic acid group (Figure 12). As a 
result, the released PS induces fluorescence 
emission and singlet oxygen generation. Par-
ticularly interesting is the fact that MacTNPs 
show enhanced photo cytotoxicity against 
activated macrophage cells as compared with 
non-activated counterparts and human dermal 
fibroblasts. The ROS-sensitive MacTNPs, 
which have an excellent target-to-background 
ratio, may have high potential for use in spe-
cific NIR fluorescent imaging and in efficient 
PDT of atherosclerosis with minimal side 
effects.[78] One year later, Ma et al. developed 
a very interesting new aPS, two-dimensional 
molecular beacon, that could be activated by 
mRNA. They obtained good efficiency of cancer imaging and 
PDT by using this new aPS as a theranostic platform.[79]
2.6. Dual­Responsive aPSs
In 2009, Ozlem and Akkaya suggested that incorporating two 
control elements into a responsive PS would make singlet 
oxygen generation even more cell selective.[80] In this approach, 
the maximum rate of singlet oxygen generation promoted by the 
PS would be reached only when two cancer related parameters 
are above threshold values, in a manner that resembles an AND 
logic gate. This concept was tested using a dual responsive aPS 
that is responsive to both acidity and Na+ concentration. In 
2014, Ng et al. developed a pH and thiol dual-responsive aPS for 
PDT.[34] This system consists of a SiPc core that is linked to two 
ferrocene quencher groups through a hydrazone and disulfide 
responsive bridges (Figure 13). These linkages are cleaved under 
mildly acidic (pH = 4.5–6.8) conditions and by biothiols, respec-
tively. Thus, in the slightly acidic and biothiol rich environment 
of cancer cells cleavage results in separation of the ferrocene 
moieties. As a result, this aPS displays a much higher photo-
cytotoxicity to tumor tissues as compared to normal tissues.[34]
Kim et al. designed a pH and temperature dual-respon-
sive lipopolymer hybrid system (Ce6@VNS) containing Ce6, 
phosphatidylcholine (PC), the pH-responsive phosphatidyle-
thanolamine (PE)-p(His) conjugate, along with the temperature 
responsive FA conjugated PE-p(NIPAM).[81] Self-assembly upon 
mixing these components creates nanospheres, which have a 
Adv. Funct. Mater. 2017, 27, 1604053
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Figure 11. Structure of HMDESeR-βGal and β-galactosidase response.
Figure 12. A schematic illustration of activatable agent for macrophage-targeted fluorescence 
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p(His) group sensitive to pH and a p(NIPAM) moiety responsive 
to temperature. Compared to free Ce6, Ce6@VNS has a signifi-
cantly enhanced photocytotoxicity against targeted KB cells.[81]
In a more recent report, Torres et al. also described a pH and 
thiol dual-responsive aPS that contains a pyrene-modified SiPc 
group, which should attract great interest as a multifunctional 
theranostic agent.[82]
Recently, Liu et al. described a series of special fluorophores 
that possess aggregation-induced emission (AIE) characteristics 
that can be used advantageously in the design of new aPSs.[83–85] 
One system is a dual-selective enzyme-responsive bioprobe con-
taining a PS for cancer-specific imaging and activatable PDT.[83] 
The probe is composed of four parts including an AIE fluorogen 
for imaging and PS, a GFLG peptide with cathepsin B responsive 
properties, a specific tri-Asp linker for improved hydrophilicity, 
and a cRGD-targeting group. In aqueous media, the photoactivi-
ties of the probe are quenched by the absence of exciton energy 
induced by intramolecular motions. However, fluorescence 
emission and phototoxicity of the probe are activated following 
internalization into cancer cells owing to cleavage of the GFLG 
group by cathepsin B. Efficient fluorescence emission and 
phototoxicity is only obtained in the aggregate model induced by 
the tumor-related reactivation.[83] This system serves as a proto-
type of a design for constructing aPSs that are not composed of 
quenchers/scavengers or energy acceptors.
3. Conclusion and Outlook
The field of PDT is at a stage where new approaches to design 
fluorescence imaging and singlet-oxygen-producing PSs are in 
demand. For a long time, the major activity within the area was 
limited to the synthesis and evaluation of new dyes as potential 
PSs. However, within the last decade, the focus of this activity 
has shifted and new strategies have been devised for PDT. For 
example, recent efforts have led to the development of aPSs, 
in which excited state processes are judiciously manipulated 
in response to cancer cell specific stimuli. As a result, “off-on” 
switching of singlet oxygen generation in response to cancer-
related parameters has become a very promising approach to 
design new PDT agents. Also, advances have been made in 
constructing systems in which fluorescence imaging is possible 
at the site of singlet oxygen production, making the PSs self-
contained theranostic agents.
As previously mentioned, different activation strategies 
based on the anomalies of tumor have been designed and 
constructed. However, we can safely speculate that even 
more interesting and potentially useful aPSs are likely to be 
developed according to novel activation mechanisms, which 
utilize some other cancer-related parameters such as hypoxia, 
specific metal ions, other over-expressed proteins in tumors, 
and so on. In addition, to the best of our knowledge, most of 
the existing acidity-responsive PSs are activated at pH < 6.5, 
which does not fall into the region of tumor pH. Thus, more 
attention should be paid to the more efficient and tumor-pH-
activated PSs. As the limiting factors governing PDT become 
better understood and addressed, we can expect that the clinical 
utility for this treatment modality will grow. It is clear from a 
current perspective that the introduction of the aPS concept 
has contributed greatly to this field by enabling the design of 
smarter therapeutic agents and even rudimentary information 
processing systems targeting cancer.
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